Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;25(10):1090-1094.
doi: 10.1111/resp.13912. Epub 2020 Jul 21.

Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state

Cormac McCarthy  1   2 , Stefano Savinelli  3   4 , Eoin R Feeney  3   4 , Marcus W Butler  1   2 , Cathal O'Broin  3   4 , Silke Ryan  1   2 , Lorraine O'Neill  5 , David J Murphy  6 , Charles G Gallagher  1 , Edward F McKone  1 , Sarmad Waqas  3 , Aoife Cotter  4 , Peter Doran  2 , Michael P Keane  1   2 , Patrick W Mallon  3   4
Affiliations

Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state

Cormac McCarthy et al. Respirology. 2020 Oct.
No abstract available

Keywords: COVID-19; autoimmune disease; pneumonia; viral infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Laboratory data from six coronavirus disease 2019 (COVID‐19) patients treated with tocilizumab. Day 0 (dashed line) is the day on which tocilizumab treatment was administered and data are presented prior to this and following drug administration for C‐reactive protein (mg/L) (A), ferritin (μg/L) (B), fibrinogen (g/L) (C) and lactate dehydrogenase (U/L) (D). All patients had evidence of a systemic hyperinflammatory state with resolution of inflammation following therapy. (E) SpO2:FiO2 (ratio of peripheral capillary oxygen saturation (SpO2) compared to fraction of inspired oxygen (FiO2)) per patient at four time points. Data are displayed for oxygenation at admission, immediately before tocilizumab administration (pre tocilizumab), 3 days after administration (post tocilizumab) and at the time of discharge from hospital (range: 5–9 days). (F) SpO2:FiO2 ratio range for all six patients on admission, immediately before tocilizumab administration (pre tocilizumab), 3–4 days after administration (post tocilizumab) and at the time of discharge from hospital (range: 6–8 days).
See this image and copyright information in PMC

Comment in

  • Severe COVID-19 and interleukin-6 receptor antagonist tocilizumab: Some notes of concern.
    Akinosoglou K, Gogos C. Akinosoglou K, et al. Respirology. 2020 Nov;25(11):1209. doi: 10.1111/resp.13939. Epub 2020 Sep 20. Respirology. 2020. PMID: 32954552 Free PMC article.
  • Reply.
    Savinelli S, McCarthy C, Mallon PW; All Ireland Infectious Diseases (AIID) Cohort Collaborators. Savinelli S, et al. Respirology. 2020 Nov;25(11):1210-1211. doi: 10.1111/resp.13940. Epub 2020 Sep 20. Respirology. 2020. PMID: 32954555 Free PMC article.

References

    1. Onder G, Rezza G, Brusaferro S. Case‐fatality rate and characteristics of patients dying in relation to covid‐19 in italy. JAMA. 2020; 323(8): 1775–1776. - PubMed
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62. - PMC - PubMed
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. - PMC - PubMed
    1. Chen H, Wang F, Zhang P, Zhang Y, Chen Y, Fan X, Cao X, Liu J, Yang Y, Wang B et al. Management of cytokine release syndrome related to CAR‐T cell therapy. Front. Med. 2019; 13: 610–7. - PubMed
    1. Watanabe E, Sugawara H, Yamashita T, Ishii A, Oda A, Terai C. Successful tocilizumab therapy for macrophage activation syndrome associated with adult‐onset Still's disease: a case‐based review. Case Rep. Med. 2016; 2016: 5656320. - PMC - PubMed